Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Cell-Derived vs Egg-Derived Influenza Vaccine in Healthy Adults
NCT00310804Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2005
- Primary completion
- Oct 2005
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of TIVc in influenza (4 arms), sponsored by Novartis. Primary endpoints: Geometric Mean Titers at Day 22, Geometric Mean Ratios at Day 22 and 2 more. Started Sep 2005; status: completed.
02
Drugs
TIVc
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00310804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00310804.